Liquidia Corp: Analysts Maintain Strong Buy Ratings Amid Patent Litigation
Liquidia Corporation, a biotechnology company specializing in the development of micro and nanoparticles for therapeutic delivery, has been the focus of significant financial news recently. The company, based in Morrisville, United States, is listed on the Nasdaq stock exchange and operates within the health care sector, specifically in the pharmaceuticals industry.
As of May 11, 2025, Liquidia’s stock closed at $15.75, with a 52-week high of $16.81 on February 19, 2025, and a low of $8.26 on August 18, 2024. The company’s market capitalization stands at approximately $1.19 billion. Despite a negative price-to-earnings ratio of -8.44, indicating potential concerns over profitability, several analysts have maintained a strong buy rating on Liquidia’s shares.
On May 12, 2025, Raymond James reiterated a “Strong Buy” rating on Liquidia, setting a target price of $29. Similarly, Needham maintained its stock rating and price target, reflecting confidence in the company’s future prospects. HC Wainwright & Co. also reiterated a “Buy” rating with the same $29 target, underscoring a consensus among analysts regarding the stock’s potential.
However, Liquidia faces legal challenges that could impact its operations. On May 9, 2025, United Therapeutics filed a patent infringement lawsuit against Liquidia in the U.S. District Court for the Middle District of North Carolina. The lawsuit pertains to Liquidia’s YUTREPIA, a treatment for pulmonary arterial hypertension. Despite this legal hurdle, Liquidia has provided updates indicating that the FDA approval timeline for YUTREPIA remains unaffected.
The company has been proactive in addressing the litigation, issuing multiple updates to inform stakeholders of the situation. These updates have been disseminated through various financial news platforms, including Benzinga, Finviz, and Global News Wire.
In summary, while Liquidia Corp navigates patent litigation, the company continues to receive strong support from analysts, who maintain optimistic price targets. Investors will be closely monitoring the legal proceedings and their potential impact on Liquidia’s market performance.